Pharmacological management of treatment-resistant obsessive-compulsive disorder

CNS Drugs

Volumn 25, Issue 7, 2011, Pages 585-596

  Abudy, Anat ^a   Juven Wetzler, Alzbeta ^a   Zohar, Joseph ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

Antipsychotics; Augmentation therapies; Clomipramine; Cognitive behavioural therapy; Cycloserine; Memantine; Monoamine oxidase inhibitors; Obsessive compulsive disorders; Serotonin uptake inhibitors; Tricyclic antidepressants; Venlafaxine

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CITALOPRAM; CLOMIPRAMINE; CYCLOSERINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

BRAIN DEPTH STIMULATION; COGNITIVE THERAPY; DRUG WITHDRAWAL; HUMAN; NEUROSURGERY; OBSESSIVE COMPULSIVE DISORDER; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; DRUG RESISTANCE; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; SEROTONIN UPTAKE INHIBITORS;

EID: 79959573071     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11587860-000000000-00000     Document Type: Review

References (97)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text rev. Washington, DC: American Psychiatric Association, 2000
2. Goodman W, Price L, Rasmussen S, et al. The Yale Brown Obsessive Compulsive Scale: validity. Arch Gen Psychiatry 1989; 46: 1012-6 (Pubitemid 19278230)
3. National Collaborating Centre forMental Health, National Institute for Health and Clinical Excellence. National clinical practice guideline number 31: obsessive compulsive disorder. Core interventions in the treatment of obsessive compulsive disorder and body dysmorphic disorder. London: The British Psychological Society and The Royal College of Psychiatrists, 2006, 350
4. Marazziti D, Consoli G. Treatment strategies for obsessivecompulsive disorder. Expert Opin Pharmacother 2010 Feb; 11 (3): 331-43
5. Andrews G, Cremer M, Crino R, et al. The treatment of anxiety disorders: clinician guides and patient manuals. 2nd ed. New York: Cambridge University Press, 2002
6. Boschen MJ, Drummond LM, Pillay A. Treatment of severe, treatment- refractory obsessive-compulsive disorder: a study of inpatient and community treatment. CNS Spectr 2008 Dec; 13 (12): 1056-65
7. Geller DA. Obsessive-compulsive and spectrum disorders in children and adolescents. Psychiatr Clin North Am 2006 Jun; 29 (2): 353-70
8. Eisen JL, Mancebo MA, Pinto A, et al. Impact of obsessive compulsive disorder on quality of life. Compr Psychiatry 2006; 47: 270-5 (Pubitemid 43849686)
9. Norberg MM, Calamari JE, Cohen RJ, et al. Quality of life in obsessive compulsive disorder: an evaluation of impairment and preliminary analysis of the ameliorating effects of treatment. Depress Anxiety 2008; 25: 248-59 (Pubitemid 351499904)
10. Olantnji BO, Cisler JM, Toilin DF. Quality of life in the anxiety disorders: ameta-analytic review. Clin Psychol Rev 2007; 27: 572-81 (Pubitemid 46686901)
11. Riggs DS, Hiss H, Foa EB. Marital distress and the treatment of obsessive compulsive disorder. Behav Ther 1992; 23: 585-93
12. Leon AC, Portera L, Weissman MM. The social cost of anxiety disorders. Br J Psychiatry Suppl 1995; 27: 19-22
13. Allen A, Pallanti S. The family in the treatment of obsessivecompulsive disorder. In: Huddak R. Clinical-obsessive compulsive disorders in adults and children [online]. Available from URL: http://ebooks.cambridge.org/chapter.jsf? bid=CBO 9780511973796&cid=CBO9780511973796A019 [Accessed 2011 May 17]
14. Pallanti S, Hollander E, Bienstock C,; International Treatment Refractory OCD Consortium. Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol 2002 Jun; 5 (2): 181-91 (Pubitemid 34669829)
15. Jenike MA. Clinical practice: obsessive-compulsive disorder. N Engl J Med 2004 Jan 15; 350 (3): 259-65
16. Pallanti S, Hollander E, Goodman WK. A qualitative analysis of nonresponse: management of treatment-refractory obsessive-compulsive disorder. J Clin Psychiatry 2004; 65 Suppl. 14: 6-10
17. Foa EB, Steketee G, Milby JB. Differential effects of exposure and response prevention in obsessive-compulsive washers. J Consult Clin Psychol 1980 Feb; 48 (1): 71-9 (Pubitemid 10099273)
18. Franklin ME, Abramowitz JS, KozakMJ, et al. Effectiveness of exposure and ritual prevention for obsessive-compulsive disorder: randomized compared with nonrandomized samples. J Consult Clin Psychol 2000 Aug; 68 (4): 594-602
19. Foa EB, LiebowitzMR, KozakMJ, et al. Randomized, placebocontrolled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessivecompulsive disorder.AmJ Psychiatry 2005 Jan; 162 (1): 151-61 (Pubitemid 40095685)
20. Frost RO, Steketee G. Cognitive approaches to obsessions and compulsions: theory, assessment and treatment. Oxford: Elsevier Science, 2002
21. Kozak JM, Foa EB. Mastery of obsessive compulsive disorder: a cognitive-behavioral approach. New York: Oxford University Press, 1997
22. Wilhelm S, Steketee G. Cognitive therapy of obsessivecompulsive disorder: a guide for professionals. Oakland (CA): Harbinger Publications, 2006
23. Koran LM, Hanna GL, Hollander E, et al., American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry 2007 Jul; 164 (7 Suppl.): 5-53
24. Hollander E, Zohar J. Beyond refractory obsessions and anxiety states: toward remission. J Clin Psychiatry 2004; 65 Suppl. 14: 3-5
25. Fernandez CE, Lopez-Ibor JJ. Mono chlorimipramine in the treatment of psychiatric patients resistant to other therapies. Actas Luso Esp Neurol Psiq Ciec Afines 1967; 26: 119-47
26. Zohar J, Insel TR. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology. Biol Psychiatry 1987 Jun; 22 (6): 667-87 (Pubitemid 17101476)
27. Zohar J, Judge R. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder: OCD Paroxetine Study Investigators. Br J Psychiatry 1996 Oct; 169 (4): 468-74
28. Decloedt EH, Stein DJ. Current trends in drug treatment of obsessive-compulsive disorder. Neuropsychiatr Dis Treat 2010 May 25; 6: 233-42
29. American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder [online]. Available from URL http://www.psychiatry online.com/pracGuide/pracGuideTopic-10.aspx [Accessed 2011 Apr 5]
30. Zohar J. Escitalopram in the treatment of obsessivecompulsive disorder. Expert Rev Neurother 2008 Mar; 8 (3): 339-49
31. Rabinowitz I, Baruch Y, Barak Y. High-dose escitalopram for the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 2008 Jan; 23 (1): 49-53 (Pubitemid 350294870)
32. Ninan PT, Koran LM, Kiev A, et al. High-dose sertraline strategy for nonresponders to acute treatment for obsessive- compulsive disorder: a multicenter double-blind trial. J Clin Psychiatry 2006 Jan; 67 (1): 15-22 (Pubitemid 43213277)
33. Marazziti D, Golia F, Consoli G, et al. Effectiveness of longterm augmentation with citalopram to clomipramine in treatment-resistant OCD patients. CNS Spectr 2008 Nov; 13 (11): 971-6
34. Mundo E, Rouillon F, Figuera ML, et al. Fluvoxamine in obsessive-compulsive disorder: similar efficacy but superior tolerability in comparison with clomipramine. Hum Psychopharmacol 2001; 16 (6): 461-8 (Pubitemid 32895589)
35. Bisserbe J, Lane R, Flament M, the Franco-Belgian OCD Study Group. A double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder. Eur Psychiatry 1997; 12 (2): 82-93 (Pubitemid 27130193)
36. Stahi SM. Essential psychopharmacology: neuroscientific basis and practical applications. 2nd ed. Cambridge, UK: Cambridge University Press, 2000
37. Stahl SM. Essential psychopharmacology: neuroscientific basis and practical applications. 2nd ed. Cambridge, UK: Cambridge University Press, 2000
38. Denys D, van der Wee N, van Megen HJ, et al. A double blind comparison of venlafaxine and paroxetine in obsessivecompulsive disorder. J Clin Psychopharmacol 2003; 23 (6): 568-75 (Pubitemid 37443188)
39. Findling RL, Schwartz MA, Flannery DJ, et al. Venlafaxine in adults with attention-deficit/hyperactivity disorder: an open clinical trial. J Clin Psychiatry 1996; 57 (5): 184-9 (Pubitemid 26158852)
40. Gürkan K, Bilgic A, Türkoglu S, et al. Depression, anxiety and obsessive-compulsive symptoms and quality of life in children with attention-deficit hyperactivity disorder (ADHD) during three-month methylphenidate treatment. J Psychopharmacol 2010 Dec; 24 (12): 1810-8
41. Vallejo J, Olivares J, Marcos T, et al. Clomipramine versus phenelzine in obsessive-compulsive disorder: a controlled clinical trial. Br J Psychiatry 1992 Nov; 161: 665-70
42. Jenike MA, Baer L, Minichiello WE, et al. Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. Am J Psychiatry 1997 Sep; 154 (9): 1261-4 (Pubitemid 27369178)
43. Fineberg NA, Saxena S, Zohar J, et al. Obsessive-compulsive disorder: boundary issues. CNS Spectr 2007 May; 12 (5): 359-64, 367-75
44. Denys D, Zohar J,Westenberg HG. The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. J Clin Psychiatry 2004; 65 Suppl. 14: 11-7
45. Bloch MH, Landeros-Weisenberger A, Kelmendi B, et al. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 2006 Jul; 11 (7): 622-32 (Pubitemid 43989810)
46. McDougle CJ, GoodmanWK, Leckman JF, et al. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: a double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 1994 Apr; 51 (4): 302-8 (Pubitemid 24127303)
47. Saxena S, Wang D, Bystritsky A, et al. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry 1996 Jul; 57 (7): 303-6 (Pubitemid 26251110)
48. McDougle CJ, Epperson CN, Pelton GH, et al. A doubleblind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000 Aug; 57 (8): 794-801 (Pubitemid 30650116)
49. Hollander E, Baldini Rossi N, Sood E, et al. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2003 Dec; 6 (4): 397-401 (Pubitemid 38146258)
50. DAmico G, Cedro C, Muscatello MR, et al. Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2003 Jun; 27 (4): 619-23 (Pubitemid 36645062)
51. Bogetto F, Bellino S, Vaschetto P, et al. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. Psychiatry Res 2000 Oct 30; 96 (2): 91-8
52. Shapira NA, Ward HE, Mandoki M, et al. A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine- refractory obsessive-compulsive disorder. Biol Psychiatry 2004 Mar 1; 55 (5): 553-5 (Pubitemid 38338545)
53. Denys D, Fineberg N, Carey PD, et al. Quetiapine addition in obsessive-compulsive disorder: is treatment outcome affected by type and dose of serotonin reuptake inhibitors? Biol Psychiatry 2007 Feb 1; 61 (3): 412-4 (Pubitemid 46108696)
54. Fineberg NA, Stein DJ, Premkumar P, et al. Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessivecompulsive disorder: a meta-analysis of randomized controlled treatment trials. Int Clin Psychopharmacol 2006 Nov; 21 (6): 337-43 (Pubitemid 44498275)
55. Atmaca M, Kuloglu M, Tezcan E, et al. Quetiapine augmentation in patients with treatment resistant obsessivecompulsive disorder: a single-blind, placebo-controlled study. Int Clin Psychopharmacol 2002 May; 17 (3): 115-9 (Pubitemid 34442192)
56. Denys D, de Geus F, van Megen HJ, et al. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry 2004 Aug; 65 (8): 1040-8
57. Fineberg NA, Sivakumaran T, Roberts A, et al. Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study. Int Clin Psychopharmacol 2005 Jul; 20 (4): 223-6 (Pubitemid 40896377)
58. Mohr N, Vythilingum B, Emsley RA, et al. Quetiapine augmentation of serotonin reuptake inhibitors in obsessivecompulsive disorder. Int Clin Psychopharmacol 2002 Jan; 17 (1): 37-40 (Pubitemid 34056524)
59. Pessina E, Albert U, Bogetto F, et al. Aripiprazole augmentation of serotonin reuptake inhibitors in treatmentresistant obsessive-compulsive disorder: a 12-week open-label preliminary study. Int Clin Psychopharmacol 2009 Sep; 24 (5): 265-9
60. Metin O, Yazici K, Tot S, et al. Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial. Hum Psychopharmacol 2003 Aug; 18 (6): 463-7 (Pubitemid 37038343)
61. March JS, Franklin ME, Leonard H, et al. Tics moderate treatment outcome with sertraline but not cognitive-behavior therapy in pediatric obsessive-compulsive disorder. Biol Psychiatry 2007 Feb 1; 61 (3): 344-7 (Pubitemid 46108694)
62. Matsunaga H, Nagata T, Hayashida K, et al. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder. J Clin Psychiatry 2009 Jun; 70 (6): 863-8
63. McDougle CJ, Price LH, Goodman WK, et al. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. J Clin Psychopharmacol 1991 Jun; 11 (3): 175-84
64. Mula M, Pini S, Cassano GB. The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J Clin Psychopharmacol 2007 Jun; 27 (3): 263-72 (Pubitemid 46763308)
65. McDougle CJ, Goodman WK, Leckman JF, et al. Limited therapeutic effect of addition of buspirone in fluvoxaminerefractory obsessive-compulsive disorder. Am J Psychiatry 1993 Apr; 150 (4): 647-9 (Pubitemid 23109937)
66. Barr LC, Goodman WK, Anand A, et al. Addition of desipramine to serotonin reuptake inhibitors in treatmentresistant obsessive-compulsive disorder. Am J Psychiatry 1997 Sep; 154 (9): 1293-5 (Pubitemid 27369184)
67. Stahl SM. Essential psychopharmacology, neuroscientific basis and practical applications. 3rd ed. San Diego (CA): Cambridge University Press, 2008
68. Pallanti S, Quercioli L, Bruscoli M. Response acceleration with mirtazapine augmentation of citalopram in obsessivecompulsive disorder patients without comorbid depression: a pilot study. J Clin Psychiatry 2004 Oct; 65 (10): 1394-9
69. Koran LM, Gamel NN, Choung HW, et al. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation. J Clin Psychiatry 2005 Apr; 66 (4): 515-20 (Pubitemid 40593581)
70. Diniz JB, Shavitt RG, Pereira CA, et al. Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial. J Psychopharmacol 2010 Mar; 24 (3): 297-307
71. Abramowitz JS, Taylor S, McKay D. Obsessive-compulsive disorder. Lancet 2009 Aug 8; 374 (9688): 491-9
72. Figee M, Denys D. New pharmacotherapeutic approaches to obsessive-compulsive disorder. CNS Spectr 2009 Feb; 14 (2 Suppl. 3): 13-23
73. Van Ameringen M, Mancini C, Patterson B, et al. Topiramate augmentation in treatment-resistant obsessivecompulsive disorder: a retrospective, open-label case series. Depress Anxiety 2006; 23 (1): 1-5
74. Coric V, Milanovic S, Wasylink S, et al. Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder. Psychopharmacology (Berl) 2003 May; 167 (2): 219-20 (Pubitemid 36628165)
75. Aboujaoude E, Barry JJ, Gamel N. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. J Clin Psychopharmacol 2009 Feb; 29 (1): 51-5
76. Stewart SE, Jenike EA, Hezel DM, et al. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. J Clin Psychopharmacol 2010 Feb; 30 (1): 34-9
77. Feusner JD, Kerwin L, Saxena S et al. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial. Psychopharmacol Bull 2009; 42 (1): 81-93
78. Hewlett WA, Schmid SP, Salomon RM. Pilot trial of ondansetron in the treatment of 8 patients with obsessivecompulsive disorder. J Clin Psychiatry 2003 Sep; 64 (9): 1025-30 (Pubitemid 37158247)
79. Pallanti S, Bernardi S, Antonini S, et al. Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study. CNS Drugs 2009 Dec 1; 23 (12): 1047-55
80. Lundberg S, Carlsson A, Norfeldt P, et al. Nicotine treatment of obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2004 Nov; 28 (7): 1195-9 (Pubitemid 40017638)
81. Taylor LH, Kobak KA. An open-label trial of St. Johns wort (Hypericum perforatum) in obsessive-compulsive disorder. J Clin Psychiatry 2000 Aug; 61 (8): 575-8
82. Hewlett WA, Vinogradov S, Agras WS. Clomipramine, clonazepam, and clonidine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 1992 Dec; 12 (6): 420-30
83. Crockett BA, Churchill E, Davidson JR. A double-blind combination study of clonazepam with sertraline in obsessive- compulsive disorder. Ann Clin Psychiatry 2004 Jul-Sep; 16 (3): 127-32 (Pubitemid 39281271)
84. Pigott TA, LHeureux F, Rubenstein CS, et al. A doubleblind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1992 Jun; 12 (3): 156-62
85. Insel TR, Hamilton JA, Guttmacher LB, et al. D-amphetamine in obsessive-compulsive disorder. Psychopharmacology (Berl) 1983; 80 (3): 231-5 (Pubitemid 13078839)
86. Joffe RT, Swinson RP, Levitt AJ. Acute psychostimulant challenge in primary obsessive-compulsive disorder. J Clin Psychopharmacol 1991 Aug; 11 (4): 237-41
87. Koran LM, Aboujaoude E, Gamel NN. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2009 Nov; 70 (11): 1530-5
88. Amiaz R, Fostick L, Gershon A, et al. Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study. Eur Neuropsychopharmacol 2008 Jun; 18 (6): 455-61
89. Dannon PN, Sasson Y, Hirschmann S, et al. Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial. Eur Neuropsychopharmacol 2000 May; 10 (3): 165-9 (Pubitemid 30227616)
90. Mundo E, Guglielmo E, Bellodi L. Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study. Int Clin Psychopharmacol 1998 Sep; 13 (5): 219-24 (Pubitemid 28470313)
91. Fux M, Benjamin J, Belmaker RH. Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a double-blind cross-over study. Int J Neuropsychopharmacol 1999 Sep; 2 (3): 193-5
92. Pallanti S, Quercioli L, Koran LM. Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. J Clin Psychiatry 2002 Sep; 63 (9): 796-801
93. Koran LM, Sallee FR, Pallanti S. Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder. Am J Psychiatry 1997 Mar; 154 (3): 396-401 (Pubitemid 27098291)
94. Koran LM, Pallanti S, Paiva RS, et al. Pulse loading versus gradual dosing of intravenous clomipramine in obsessivecompulsive disorder. Eur Neuropsychopharmacol 1998 May; 8 (2): 121-6 (Pubitemid 28210338)
95. Fallon BA, Liebowitz MR, Campeas R, et al. Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study. Arch Gen Psychiatry 1998 Oct; 55 (10): 918-24 (Pubitemid 28465782)
96. Koran LM, Aboujaoude E, Ward H, et al. Pulse-loaded intravenous clomipramine in treatment-resistant obsessivecompulsive disorder. J Clin Psychopharmacol 2006 Feb; 26 (1): 79-83 (Pubitemid 43167096)
97. Vulink NC, Denys D, Fluitman SB, et al. Quetiapine augments the effect of citalopram in non-refractory obsessive- compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients. J Clin Psychiatry 2009 Jul; 70 (7): 1001-8